PART I Overview We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer growth, metastasis and progression, and contribute to immunotherapy, chemotherapy and radiotherapy resistance. The DNase technology is designed to targe...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001683168-26-001737 | EDGAR | 67K words |
| 2025-03-18 | 2024-12-31 | 0001683168-25-001686 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001683168-24-001594 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0001683168-23-001674 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001683168-22-001839 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001683168-21-000969 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001683168-20-000967 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001683168-19-000840 | EDGAR | — |
| 2018-03-30 | 2017-12-31 | 0001683168-18-000831 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001683168-17-000749 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001683168-25-008259 | EDGAR | 14K words |
| 2025-08-12 | 2025-06-30 | 0001683168-25-005983 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001683168-25-003496 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001683168-24-007903 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001683168-24-005572 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001683168-24-003172 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001683168-23-007820 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001683168-23-005513 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001683168-23-003201 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001683168-22-007447 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001683168-22-005567 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001683168-22-003503 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001683168-26-001744 | EDGAR | 1K words |
| 2026-01-09 | 0001683168-26-000196 | EDGAR | — |
| 2025-12-11 | 0001683168-25-009076 | EDGAR | — |
| 2025-11-13 | 0001683168-25-008288 | EDGAR | — |
| 2025-10-14 | 0001683168-25-007528 | EDGAR | — |
| 2025-08-13 | 0001683168-25-006001 | EDGAR | — |
| 2025-05-14 | 0001683168-25-003513 | EDGAR | — |
| 2025-04-10 | 0001683168-25-002396 | EDGAR | — |
| 2025-03-19 | 0001683168-25-001693 | EDGAR | — |
| 2024-12-13 | 0001683168-24-008712 | EDGAR | — |
250 total filings indexed. 218 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001534525 |
| Ticker | XBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.xeneticbio.com |
| Listed | 2012-05-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report